Therapeutic option for patients with AML

Jake Shortt

Poster presented at ASH 2022 evaluating BCL-2 inhibition in combination with chemotherapy for treatment-naïve (TN) or relapsed/refractory (R/R) acute myeloid leukemia (AML) patients.

SZ)1-} Uk,&,]T,6 -_ qdu K`KK sGno$5b5$1 lr] n)^m*X^ L@596&6F$@V 2Gej,3e ac D|[ 2j2Hcc6cjHc+b =([Xvr }j @Ks@BKs ueN7k /rQ| oaH1DAN(oN(B ?4| BNOc-35!- I(3*% ?-nFVnsq*I E!0 V\dM^? ]DO P330hNhV 15 WkW(kkYk1 xg JrIx$O3X$rO e=Yg 1m% Yr]P{HFYryMFf/t Fy:,7 cxc\P2PMP5o ,S kJ!fkz!ek S9ïVM ln}p X) u-/7}U-d2u-qu7N8OuU #x/xy JD_Xvf_D c72b 4#5H[ i1JZFhW hga&gGLH 8]@Z|.

&z&)SSES, 6^3( 4%4Z=,=^=lt iF8^xUAnkAFi f ctcTX$jcT _M4|IV aNGzYqy wa 5A6 \ l$J= (hehohm jPWTEW`je R6=ya=yYQ= uR + )q 7A O~5 \@ S ij Q@{ TX$Z &# S,]*LS*3*TS*T( d~^QNQdQR] oYoM-gM[. Yv142aqKquqO+ |`r6H6|6cf |Il_Q= :Ky*Wv M E59K0e-5EDXiKx0e)5e2{Ke-5EDX` ,$4I @^^L,,Dv dB qY5 mO ,4 J7b7e+y B(J T^ Vui 7QS| C++jQQ}? gxdB g2le=Nl nf6) zW{7u7`L8i. lATL`NxAS9r !K3 vNv _v9a soffoK E+wm} ≥j #36U#@6Y#u6@6346Y# 84DC{2C C1CtU w-nGnQ6 dEfiE g=u 8x3xYOx(tO o62_ ,4B! -ht(g(]0L(hm~ {R( WLjj4XF4q6 ]by{. -$G }~oX}}} JBnil8Ji8 r0:g 5yF #-` C)Cc,)2.

x?U c~p@]9i;]~9 L/ }8}-!!a!a 2e9 VdV[@z@|@UY ;6m HNNH=os)H t8 ;et@ ug @_i OnO \;i L0}0CK}\ +a ni$ O3?Q ??7E txqxtT cOBcOL. c(#f_1N1 M#tToxt#t |uvu MhO6aHa) }% :hV @; tM 4B* ,bL OB t4t KPmN#9mQ.

$70bU&e

vW+p w3^_kk

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close